Get the Weekly Intelligence Brief — top committee picks every Sunday.
ITGR · NYSE · STOCK

Integer Holdings (ITGR) Stock Analysis

Healthcare Updated October 10, 2026
$126.61
52W $62.00 – $126.80
59/100
$4.30B
34.3
0.58
AI Committee Verdict
Buy
59/100
Conviction: Contested · 50% agreement · 6 analysts
+0.1%
-17.1%
0.01:1
Contested
⚠
Buy rating, but near-term risk/reward is unfavorable
The long-term recommendation is based on the composite investment score. The near-term risk/reward is based on nearby support and resistance levels. These can differ when a strong company trades close to resistance with support further below.

Is ITGR Bullish or Bearish?

Bullish. Innellis AI committee rates Integer Holdings Corporation (ITGR) Buy with a composite score of 59/100 , based on 6 analysts with 50% agreement. Last updated October 10, 2026.

What Would Change This View

Upgrade to Strong Buy
Requires a committee score of 75.0 — +16.04 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Watch
Requires the score to fall below 55.0 — -3.96 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

The committee is genuinely divided. Growth Analyst sees a compelling case — eps growing 62.0% yoy. Portfolio Manager remains cautious — sector concentration is already high (hhi 2796.97). This disagreement is itself the signal — the setup is not clean in either direction.

Bull & Bear Case

Bull Case
  • EPS growing 62.0% YoY — Growth
  • Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
  • Price structure making higher highs and higher lows — Technical
  • Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
  • P/E of 33.5 is moderate-to-rich — Value
  • RSI at 73 is in overbought territory — Technical
  • MACD histogram negative -- bearish momentum — Technical
  • Daily trend (uptrend) conflicts with the weekly trend (downtrend) -- fighting the larger trend — Technical
  • Weekly RSI at 91 -- overbought on the larger timeframe too — Technical
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of October 10, 2026
Overall Committee Score
59/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 39%
of 192 Healthcare peers
Value Analyst neutral
48 / 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
− P/E of 33.5 is moderate-to-rich
Growth Analyst bullish
70 / 100 · High confidence
Strong, accelerating growth with consistent execution
+ EPS growing 62.0% YoY
Technical Analyst neutral
44 / 100 · High confidence
Mixed or range-bound price action
+ Price structure making higher highs and higher lows
− RSI at 73 is in overbought territory
Risk Analyst bullish
70 / 100 · Low confidence
Risk profile is manageable -- leverage, volatility, and event exposure all look contained
Macro Analyst bullish
65 / 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst neutral
58 / 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager bearish
30 / 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Open Full Terminal →

Investment Thesis Evolution

Committee score moved marginally from 59.0 to 59.0.

Analyst-level changes:
  • Technical Analyst: +1 bearish signal(s).

Comparing 2026-10-09 to 2026-10-10 (1 day apart).

Technical Analysis

RSI (14)
73.3
Overbought
MACD Histogram
-0.286
Bearish Momentum
Trend Direction
Uptrend
Weekly: Downtrend
Market Structure
Hh Hl
Support
$104.97
Resistance
$126.74
Bollinger %B
0.91
Inside Bands
Price vs Moving Averages
EMA 9
$126.51 Above
EMA 21
$126.07 Above
EMA 50
$121.66 Above
EMA 200
$105.40 Above

Fundamental Analysis

Valuation
69
Growth
65
Profitability
26
Financial Health
93
Cash Flow
70
Valuation
P/E Ratio 34.3×
P/B Ratio 2.51×
PEG Ratio 0.65
Dividend Yield 0.00%
52W High $126.80
52W Low $62.00
Quality & Growth
ROE 588.3%
ROA 301.3%
Gross Margin 2373.1%
Operating Margin 947.2%
Revenue Growth YoY —
Debt / Equity 0.79
AI Fundamental Assessment
P/E ratio of 34.3 (rich relative to a 15-40x range); Price-to-book of 2.5x; PEG ratio of 0.7 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 5.9%; Return on assets of 3.0%; Net margin of 7.0%; Gross margin of 23.7%; Current ratio of 3.73 (healthy short-term liquidity); Debt-to-equity of 0.79; Free cash flow per share is positive (3.29); Most recent quarter beat estimates by 10.9%; EPS growth accelerating (-31.8% -> +33.3% QoQ); Analyst estimates falling over recent quarters
Get the Full ITGR Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime